VCN BIOSCIENCES
VCN Biosciences specializes in the research and development of new treatments for tumors based on a technological platform using oncolytic viruses.
VCN BIOSCIENCES
Social Links:
Industry:
Biotechnology
Founded:
2009-01-01
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Website Url:
http://www.vcnbiosciences.com
Total Employee:
11+
Status:
Active
Contact:
34 60 943 23 75
Email Addresses:
[email protected]
Technology used in webpage:
DreamHost Hosting Semantic UI
Similar Organizations
Animal Cell Therapies
Animal Cell Therapies engages in the research and development of stem cell treatments for acute and chronic diseases in companion animals.
Biomedical Tissues
Biomedical Tissues is specialised in the research and development of implantable medical devices for the regeneration of human tissue.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Current Advisors List
Current Employees Featured
Investors List
Grifols
Grifols investment in Funding Round - VCN Biosciences
Official Site Inspections
http://www.vcnbiosciences.com
- Host name: utopicus-usina.com
- IP address: 208.113.185.7
- Location: Brea United States
- Latitude: 33.9339
- Longitude: -117.8854
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 92821
More informations about "VCN Biosciences"
Synthetic Biologics Completes Acquisition of VCN Biosciences
Mar 11, 2022 · VCN is a privately held clinical-stage biotech company focused on developing a new oncolytic adenovirus (OV) platform designed for intravenous (IV) and intravitreal (IVit) …See details»
VCN Biosciences - Crunchbase Company Profile & Funding
VCN Biosciences specializes in the research and development of new treatments for tumors based on a technological platform using oncolytic viruses. VCN Biosciences was acquired by …See details»
Synthetic Biologics Announces Planned Transformative
ROCKVILLE, Md., Dec. 14, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases …See details»
Grifols moves forward with its divestment plan by agreeing to sell …
Dec 14, 2021 · Under this agreement, Grifols will oversee a smooth transition of all VCN Biosciences operations, while Synthetic Biologics will continue to promote and finance VCN’s …See details»
Theriva Biologics (formerly VCN Biosciences) | LinkedIn
Theriva is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells.See details»
VCN Biosciences - ASEBIO
VCN Biosciences SL is a company focused in the development of new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology …See details»
VCN Biosciences - PitchBook
Information on acquisition, funding, investors, and executives for VCN Biosciences. Use the PitchBook Platform to explore the full profile.See details»
Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives …
Feb 8, 2022 · VCN is developing a new oncolytic adenovirus (OV) platform designed to trigger tumor cell death and promote immune cell infiltration into tumors.See details»
VCN Biosciences - Craft
VCN Biosciences is a company focused on the development of therapeutic approaches for tumor treatment. It uses an oncolytic adenovirus technology platform to design highly selective …See details»
VCN Biosciences SL | Insights
Aug 16, 2022 · Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Oncolytic adenovirus VCN-01 turns cold tumors hot - Nature
Clinical-stage immuno-oncology company VCN Biosciences is developing a portfolio of its own uniquely designed therapeutic oncolytic adenovi-ruses.See details»
Manel Cascallo / VCN Biosciences open innovation case | PPT
Apr 30, 2014 · Presentation given by Manel Cascallo, from VCN Biosciences, in the framework of the Emergence Forum Barcelona Biocat organized the Barcelona Emergence Forum (April 10 …See details»
Oncolytic adenovirus VCN-01 turns cold tumors hot - Nature
Clinical-stage immuno-oncology company VCN Biosciences is developing a portfolio of its own uniquely designed therapeutic oncolytic adenoviruses.See details»
Synthetic Biologics Announces Planned Transformative ... - BioSpace
Dec 14, 2021 · VCN's technology platform is designed to overcome critical challenges that restrict the development of the majority of OV therapies today. Unlike many OVs that can only be …See details»
DELIVERING A NEW CLASS OF ONCOLYTIC VIRUS THERAPEUTICS
Oct 16, 2024 · Theriva is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor …See details»
Engineering living therapeutics with synthetic biology
Oct 6, 2021 · We present notable advances in the creation of engineered cells that harbour synthetic gene circuits capable of biological sensing and computation of signals derived from …See details»
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor …
VCN-01 is an oncolytic adenovirus designed to replicate in cancer cells with a dysfunctional RB1 pathway and express hyaluronidase. Here, we evaluated the mechanism of action of VCN-01 …See details»
Oncolytic adenovirus with hyaluronidase activity that evades ...
Apr 10, 2021 · VCN-11 is a novel oncolytic adenovirus, genetically modified to express hyaluronidase (PH20) and display an albumin-binding domain (ABD) on the hexon. ABD …See details»